Back to top
more

Encompass Health (EHC)

(Delayed Data from NYSE)

$103.53 USD

103.53
693,737

+1.62 (1.59%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $103.58 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y

by Zacks Equity Research

Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.

Acadia (ACHC), Geisinger JV Begin Construction of New Hospital

by Zacks Equity Research

The new hospital from Acadia (ACHC) and Geisinger JV is scheduled to open in spring 2025.

Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down

by Zacks Equity Research

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.

Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down

by Zacks Equity Research

Phibro's (PAHC) impressive fiscal 2024 third-quarter performance continues to be driven by the Animal Health segment.

National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.

Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and The Pennant Group

by Zacks Equity Research

DaVita, Encompass Health, Option Care Health and The Pennant Group have been highlighted in this Industry Outlook article.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1

by Zacks Equity Research

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.

Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand

by Zacks Equity Research

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Debanjana Dey headshot

4 Stocks to Buy in a Thriving Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.

Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View

by Zacks Equity Research

Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.

Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.

The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant

by Zacks Equity Research

DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.

Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View

by Zacks Equity Research

Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.

Nalak Das headshot

Top 5 Outpatient and Home Healthcare Stocks for Solid Returns

by Nalak Das

We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.

Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y

by Zacks Equity Research

Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.

Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens

by Zacks Equity Research

Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.

Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View

by Zacks Equity Research

Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Ritujay Ghosh headshot

4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts

by Ritujay Ghosh

Investing in defensive stocks like ResMed Inc. (RMD), Encompass Health Corporation (EHC), New Jersey Resources Corporation (NJR) and Global Water Resources, Inc. (GWRS) would be a wise idea during these times of uncertainty.

Should Value Investors Buy Encompass Health (EHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

EHC or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed

by Zacks Equity Research

IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.

Teladoc Health (TDOC) Q1 Loss Widens on Decline in Visits

by Zacks Equity Research

Teladoc Health's (TDOC) Q1 results suffer from weak contributions from the BetterHelp unit. Management expects U.S. Integrated Care Members of 92-94 million for 2024, up from the prior mentioned 90-92 million.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.